Tillmanns Todd, Masri Amal, Stewart Chelsea, Chase Dana, Karnezis Anthony, Chen Lee-May, Urban Renata
WEST Clinic / University of Tennessee Health Science Center, Memphis, TN, USA.
University of California, Los Angeles, CA, USA.
Gynecol Oncol Rep. 2024 Jul 18;55:101462. doi: 10.1016/j.gore.2024.101462. eCollection 2024 Oct.
In February of 2024, the Society of Gynecologic Oncology (SGO) hosted a journal club focused on new treatment options for the management of advanced and metastatic endometrial cancer. This clinical commentary is intended to provide a summary report of that presentation. The session described the importance of molecular characterization shown in the work of The Cancer Genome Atlas (TCGA). The updated 2023 FIGO staging of endometrial cancer was reviewed. The panel then described the role of upfront immunotherapy for the treatment of advanced or recurrent endometrial cancer as demonstrated in four recent trials (RUBY, NRG-GY018, AtTEnd, and DUO-E studies). The DUO-E study uniquely examined the combination immunotherapy with a PARP inhibitor. The trials had unique differences in inclusion criteria, primary outcomes, and length of maintenance therapy, but all boasted similarly promising results particularly in mismatch repair deficient (dMMR) endometrial cancer. This era of rapid innovation in advanced and recurrent endometrial cancer will hopefully enhance individualized treatment approaches and improved outcomes for patients with endometrial cancer.
2024年2月，妇科肿瘤学会（SGO）举办了一次期刊俱乐部活动，重点讨论晚期和转移性子宫内膜癌治疗的新选择。本临床评论旨在提供该报告的总结。会议介绍了癌症基因组图谱（TCGA）研究中分子特征的重要性。回顾了2023年更新的国际妇产科联盟（FIGO）子宫内膜癌分期。专家小组随后介绍了四项近期试验（RUBY、NRG-GY018、AtTEnd和DUO-E研究）中显示的一线免疫疗法在晚期或复发性子宫内膜癌治疗中的作用。DUO-E研究特别探讨了免疫疗法与PARP抑制剂的联合使用。这些试验在纳入标准、主要结局和维持治疗时长方面存在独特差异，但均取得了同样令人鼓舞的结果，尤其是在错配修复缺陷（dMMR）子宫内膜癌方面。晚期和复发性子宫内膜癌的快速创新时代有望增强个体化治疗方法，并改善子宫内膜癌患者的治疗效果。
